Navigation Links
Phase II Clinical Trial Results Encouraging for PA-Based Women's Health Company
Date:1/11/2011

WAYNE, Pa., Jan. 11, 2011 /PRNewswire/ -- FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder (OAB).

The Phase II FP 1097 trial demonstrated that drug can be delivered to the bladder via intra-vaginal administration successfully. The clinical trial showed a statistically significant 25 percent reduction of micturitions and a 75 percent reduction of incontinence episodes. Treatment-related adverse events were low with no serious adverse events and all subjects completing the trial. Over 50 percent of the patients on FP 1097 achieved total continence.

Based on the results, FemmePharma Global Healthcare was granted permission to proceed to a pivotal Phase III trial by the Food and Drug Administration (FDA). In addition the FDA will grant FemmePharma 505B1 filing status for FP 1097.

According to published reports, it is estimated that more than 30 million Americans (mostly women) experience OAB. IMS Healthcare estimates that the OAB prescription market in the United States exceeds $2.0 billion annually while the total worldwide market including drugs, diapers and devices exceeds $7.0 billion annually.

"The encouraging safety and efficacy results from this randomized study of FP 1097 provides a basis to advance this innovative product into Phase III clinical development," said Gerianne DiPiano, founder, President and CEO of FemmePharma Global Healthcare, Inc.


'/>"/>
SOURCE FemmePharma Global Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
2. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
3. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
4. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
6. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
7. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
10. Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
11. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... 2014 Research and Markets has announced ... 2014-2018" report to their offering. ... a technique used to determine the size of a particle ... crucial to analyze the size of particles as it can ... is performed to determine the behavior and nature of a ...
(Date:7/25/2014)... in each person,s digestive tract. Scientists believe that some ... harmful infections, but their role in human health is ... the role of these bacteria, a team of researchers ... fluctuations in the bacterial populations of two research subjects ... July 25 issue of the journal Genome Biology ...
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... Authorities to Launch Final ... Clinical Trial for Asacard(R), NEW ... appointment of Dr. Geert Cauwenbergh as Chief Executive,Officer. Dr. Cauwenbergh ... assisting RHEI Pharmaceuticals since August 1, 2008,in providing the necessary ...
... (IPM) today announced it was named to Inc. ... companies nationwide for a second consecutive year. The ... broad range of industries, helping companies operate more ... one of the Chicago area’s top 100 businesses, ...
... Mymetics,Corporation (OTCBB:MYMX) announced today that its ... & Poor,s Market Access Program, an,information distribution ... have their company information disseminated to users ... information to be made,available through this program ...
Cached Biology Technology:RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 2RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 3RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 4 Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area 2Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program 2
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Barts Cancer Institute have found that targeting a molecule ... effective, according to research published in Nature ... of Queen Mary University of London, have found that ... body to repair itself after chemotherapy or radiotherapy, which ... removed FAK from blood vessels that grew in melanoma ...
(Date:7/25/2014)... 100,000s of people lived on the land now called ... control the availability of plants they used for food, ... fire to maintain desired habitat and natural resources. , ... Pacific Southwest Station, will lead a field trip ... the Ecological Society of America,s 99th Annual Meeting, in ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... Calif., Jan. 10, 2011 Based on its ... Frost & Sullivan recognizes Cardiocom with the 2011 ... Technology. Cardiocom provides integrated clinical telehealth services that ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) ...
... Dry Copper Kills Bacteria on Contact ... their populations, according to a paper in the February ... Microbiology . They do so literally in minutes, by ... says the study,s corresponding author, Gregor Grass of the ...
... China, Feb. 1, 2011/PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group ... ) ("Weikang" or the "Company"), a leading developer, ... Western prescription and OTC pharmaceuticals and other health ... China, today announced the completion of its private ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Tips from the journals of the American Society for Microbiology 5Tips from the journals of the American Society for Microbiology 6Tips from the journals of the American Society for Microbiology 7Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... been designed to save time and provide ... in eliminating the recycling and resterilizing necessary ... packaged, RNase/DNase free, non-pyrogenic and antistatic. Linkage: ... number, created to easily match Cornings product ...
... spatulas have been designed to save time ... those interested in eliminating the recycling and ... is individually packaged, RNase/DNase free, non-pyrogenic and ... new product number, created to easily match ...
... a base medium for preparation of minimal and ... but does not contain amino acids. Both bulk ... pouch contains reagents to prepare 500 ml of ... of 10X YNB for S. cerevisiae media. Store ...
Biology Products: